Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Berobenatide

A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)

Pfizer · Phase 3 · Recruiting · Enrollment 180

NCT07794761

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Treatment Arm 2n/rn/rn/rn/r
Placebon/rn/rn/rn/r
Treatment Arm 3n/rn/rn/rn/r
Treatment Arm 1n/rn/rn/rn/r

Not shown

  • Treatment Arm 2: endpoint not reported
  • Placebo: endpoint not reported
  • Treatment Arm 3: endpoint not reported
  • Treatment Arm 1: endpoint not reported